The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Ozempic-curious people are taking a novel approach to using the blockbuster weight loss drug — and some doctors are even ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

Analysts at JPMorgan Chase & Co. last week flagged that Novo Nordisk’s third-quarter results in November may show slower-than ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...